The Early/Expanded Access Committee has announced the addition of a new site in Atlanta, Ga for the trial of MDV-3100. According to my sources, there will be even more sites added in the near future.

The role of the trial is to provide expanded Access to MDV3100 and monitor its safety in men with progressive castration-resistant prostate cancer that has been previously treated with docetaxel based chemotherapy.

No placebo – No cost for MDV3100 (Enzalutamide)
You should check with the trial site for any other costs you might incur.

PeachTree Hematology Oncology Consultants
Contact: Ann Johnston (678) 298-3241
Atlanta, GA


Alaska Clinical Research Center, LLC
Contact: Robin Adams (907) 276-1455
Anchorage, Alaska 99508

Pinnacle Oncology/Hematology
Contact: Sherril Bierman (480) 278-8804
Scottsdale, AZ 85258

Prostate Oncology Specialists
Contact: Jennifer Leung (310) 827-7707
Marina del Rey, CA 90292

Dr Ronald Yanagihara
Contact: Katrina or Lara (408) 847-6194
Gilroy, CA 95020

Investigative Clinical Research of Indiana LLC
Contact: Leslie Weitman (317) 716-0323
Indianapolis, IN, 46260

Jackson Oncology Associates, PLLC
Contact: Teresa Davis (601) 974-5547
Jackson, Mississippi, 39202

New Hampshire
New Hampshire Oncology Hematology PA
Contact: Margaret White (603) 224-2556 x 1323
Hooksett, New Hampshire, 03106

New York
Accumed Research Associates
Contact: Tammi Allegra (516) 746-2190
Garden City, New York, 11530

North Carolina
Cancer Centers of North Carolina
Contact: Julia Berry (919) 781-7070
Raleigh, North Carolina, 27607

South Carolina
Charleston Hematology Oncology Associates, PA
Contact: Deborah McNeal (843) 266-2540
Charleston, South Carolina, 29414

Carolina Urologic Research Center
Contact: Tabitha Joyner (843) 449-1010 x228
Myrtle Beach, South Carolina, 29572

Virginia Oncology Associates
Contact: Wendi Gobhardt (757) 213-5813
Norfolk, VA, 23502

Joel T Nowak, M.A., M.S.W.